MY158251A - Method for the preparation of nalmefene hydrochloride - Google Patents

Method for the preparation of nalmefene hydrochloride

Info

Publication number
MY158251A
MY158251A MYPI2011005679A MYPI2011005679A MY158251A MY 158251 A MY158251 A MY 158251A MY PI2011005679 A MYPI2011005679 A MY PI2011005679A MY PI2011005679 A MYPI2011005679 A MY PI2011005679A MY 158251 A MY158251 A MY 158251A
Authority
MY
Malaysia
Prior art keywords
nalmefene hydrochloride
preparation
naltrexone
efficient
give
Prior art date
Application number
MYPI2011005679A
Other languages
English (en)
Inventor
Faveri Carla De
Mauro Casarin
Michele Brusegan
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43222172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY158251(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MY158251A publication Critical patent/MY158251A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI2011005679A 2009-05-25 2010-05-21 Method for the preparation of nalmefene hydrochloride MY158251A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900650 2009-05-25
US18102209P 2009-05-26 2009-05-26

Publications (1)

Publication Number Publication Date
MY158251A true MY158251A (en) 2016-09-30

Family

ID=43222172

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011005679A MY158251A (en) 2009-05-25 2010-05-21 Method for the preparation of nalmefene hydrochloride

Country Status (35)

Country Link
US (1) US8598352B2 (enExample)
EP (1) EP2435439B8 (enExample)
JP (1) JP5794980B2 (enExample)
KR (1) KR101716522B1 (enExample)
CN (1) CN102459276B (enExample)
AR (1) AR076891A1 (enExample)
AU (1) AU2010252392B2 (enExample)
BR (1) BRPI1010975B1 (enExample)
CA (1) CA2763093C (enExample)
CL (1) CL2011002974A1 (enExample)
CO (1) CO6470832A2 (enExample)
CR (1) CR20110612A (enExample)
DK (1) DK2435439T3 (enExample)
DO (1) DOP2011000362A (enExample)
EA (1) EA019331B1 (enExample)
ES (1) ES2564006T3 (enExample)
GE (1) GEP20146190B (enExample)
HR (1) HRP20160110T1 (enExample)
HU (1) HUE026892T2 (enExample)
IL (1) IL216422A (enExample)
MA (1) MA33368B1 (enExample)
ME (1) ME02622B (enExample)
MX (1) MX2011012502A (enExample)
MY (1) MY158251A (enExample)
NZ (1) NZ596988A (enExample)
PL (1) PL2435439T3 (enExample)
RS (1) RS54599B1 (enExample)
SG (1) SG176205A1 (enExample)
SI (1) SI2435439T1 (enExample)
SM (1) SMT201600061B (enExample)
TN (1) TN2011000590A1 (enExample)
TW (1) TWI469985B (enExample)
UA (1) UA106752C2 (enExample)
WO (1) WO2010136039A1 (enExample)
ZA (1) ZA201108659B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2645725T3 (es) 2010-06-11 2017-12-07 Rhodes Technologies Procesos catalizados por metales de transición para la preparación de compuestos de N-alilo y uso de los mismos
RS55777B1 (sr) 2010-11-05 2017-07-31 H Lundbeck As Postupak za proizvodnju naltreksona
CN103012416B (zh) * 2011-09-28 2015-07-01 辽宁海思科制药有限公司 一种盐酸纳美芬的制备方法
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
CN102584840A (zh) * 2011-12-28 2012-07-18 南京优科生物医药有限公司 一种制备纳美芬化合物的方法
US20140155608A1 (en) 2012-05-03 2014-06-05 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
CN103204859B (zh) * 2013-04-25 2015-12-02 四川海思科制药有限公司 一种盐酸纳美芬化合物及其制备方法
AR096851A1 (es) * 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
MX368870B (es) 2013-12-20 2019-10-21 H Lundbeck As Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas.
EP3134090B1 (en) 2014-04-22 2019-06-05 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
CN104513251A (zh) * 2014-11-28 2015-04-15 安徽悦康凯悦制药有限公司 一种盐酸纳美芬的制备方法
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
RU2712232C1 (ru) * 2018-10-05 2020-01-27 Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства Улучшенный способ получения налмефена из налтрексона
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
US20230399334A1 (en) 2020-11-02 2023-12-14 Rhodes Technologies Process for purifying noroxymorphone
US20240109907A1 (en) * 2021-01-28 2024-04-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN117843650A (zh) * 2023-12-27 2024-04-09 南京海纳医药科技股份有限公司 一种盐酸纳美芬的精制方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法
CN119080788A (zh) * 2024-08-19 2024-12-06 南京海鲸药业股份有限公司 一种盐酸纳美芬杂质的去除监控系统及去除方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341764A (en) 1980-03-05 1982-07-27 Cutter Laboratories, Inc. Method of preparing fibronectin and antihemophilic factor
US4322426A (en) * 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) * 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US7687646B2 (en) 2006-03-28 2010-03-30 Azad Pharmaceutical Ingredients, Ag Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene

Also Published As

Publication number Publication date
CR20110612A (es) 2012-02-22
KR20120023704A (ko) 2012-03-13
ES2564006T3 (es) 2016-03-17
AR076891A1 (es) 2011-07-13
GEP20146190B (en) 2014-11-10
CN102459276A (zh) 2012-05-16
EP2435439B8 (en) 2016-05-18
HRP20160110T1 (hr) 2016-03-11
MX2011012502A (es) 2011-12-12
BRPI1010975B1 (pt) 2021-08-24
TWI469985B (zh) 2015-01-21
EP2435439B1 (en) 2016-01-06
US8598352B2 (en) 2013-12-03
CL2011002974A1 (es) 2012-04-13
CA2763093A1 (en) 2010-12-02
KR101716522B1 (ko) 2017-03-14
MA33368B1 (fr) 2012-06-01
ME02622B (me) 2017-06-20
DK2435439T3 (en) 2016-02-29
AU2010252392B2 (en) 2014-10-23
SMT201600061B (it) 2016-07-01
SG176205A1 (en) 2011-12-29
TN2011000590A1 (en) 2013-05-24
JP5794980B2 (ja) 2015-10-14
CO6470832A2 (es) 2012-06-29
RS54599B1 (sr) 2016-08-31
EP2435439A1 (en) 2012-04-04
JP2012527489A (ja) 2012-11-08
US20120123123A1 (en) 2012-05-17
BRPI1010975A2 (pt) 2015-10-20
EA019331B1 (ru) 2014-02-28
CN102459276B (zh) 2016-09-21
DOP2011000362A (es) 2012-07-15
HUE026892T2 (en) 2016-07-28
SI2435439T1 (sl) 2016-06-30
CA2763093C (en) 2017-03-07
TW201043634A (en) 2010-12-16
ZA201108659B (en) 2013-02-27
IL216422A (en) 2015-06-30
IL216422A0 (en) 2012-02-29
WO2010136039A1 (en) 2010-12-02
UA106752C2 (uk) 2014-10-10
EA201171461A1 (ru) 2012-05-30
AU2010252392A1 (en) 2012-01-12
PL2435439T3 (pl) 2016-05-31
NZ596988A (en) 2013-03-28

Similar Documents

Publication Publication Date Title
TN2011000590A1 (en) Preparation of nalmefene hydrochloride from naltrexone
PT2913337T (pt) Processo para a produção de sofosbuvir
PL2261308T3 (pl) Sposób wytwarzania gazu ziemnego
ZA201201874B (en) Process for the production of butadiene
IN2012DN02751A (enExample)
IL223420A0 (en) Large-scale production of soluble hyaluronidase
EP2408725A4 (en) PROCESS FOR THE PRODUCTION OF OLEFINES
NZ605234A (en) Process for the synthesis of substituted morphinans
ZA201107805B (en) Process for the production of alcohols
EP2474517A4 (en) PROCESS FOR THE PREPARATION OF 1,1,3-TRICHLOR-1-PROPENE
IN2015MN00013A (enExample)
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц
PL2408726T3 (pl) Sposób dostarczania ciepła do konwersji chemicznej oraz proces i układ, w których stosuje się sposób wytwarzania olefiny
MY155284A (en) Process for the preparation of ajoene
UA106988C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та необхідні проміжні сполуки магнію
ZA201001962B (en) A process for the production of ambrafuran
SG178600A1 (en) Photochemical process for producing artemisinin
MY165659A (en) Novel method of preparing benzoimidazole derivatives
MX337997B (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
IL215689A (en) Two-step method in two reactors for the preparation of dimethyl ether
EP2463377A4 (en) PROCESS FOR THE PRODUCTION OF L-LYSINE USING A BACTERIUM OF THE GENUS VIBRIO
WO2011057947A3 (en) Method for producing silicon
GB0922333D0 (en) Granulate, process for the production of use thereof
EP2423187A4 (en) PROCESS FOR PRODUCING N-ALCOXYCARBONYL-tert-LEUCINS
WO2014133291A9 (ko) (2rs)-아미노-(3s)-히드록시-부티르산 또는 이의 유도체의 제조방법